Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
eNq9mE1z2jAQhu/8Co8PvdnGAVpoDZmWJi0zyYSSMO30khH2EkSF5OiDj/z6ypg0pCNPGoF6Aiz51Xp39ejFyel6QbwlcIEZ7fpxWPc9oCnLML3r+uOb86Dtn/ZqyRwt0dO0Ez0vjGPfSwkSousXo+EEEBXhj8uLz6DvB+73al7CJnNI5bN5SmISfkVidonyYo6XLBnOvAXIGcu6fq7k9qqXCMl1FL0V479EjlJIot2V/dH5bXP/ehIVYv+gqgTwC0TvjKJArTRTxTlQ2UcS7hjfVMTbsNLGYgSCKZ7CEMnZkLMlziAzLjFFRIDVItNVdg18SUAWixjFo3m6EFbiaI7WI7gfmIP+qEf7ci2DehC/6zTiZrtT7zTrdsnie6kyV0E/RJTfNpqdeqPVjIBGZENzxB9QwAjSX/AkYEv9gWiQIpoCtyzakHGJiKNyYdF/3nGO1uFw/2JbZFjkBG3CuchtU4U40sPANRfcPUjxBDdck4ronP2lTxUh0SujHu844ijiAlN9pqiswMn5yDYRfUYlrKsrakdAud71IgZxPNkHRs30H6oJwakt6zSNFAg5Hg2qUfdfKPEJCRhzd5j4jmnGVuL4+Nkvt6Po8y1BjaI5z+Lbk077bdxqWe+un7q3Ks6kM8VZDpEGExaH8GZAp+xQ0uh2NUs9Nqv7Pt1aJpYiAhWmKbCkkW7QR4/nbAu4217lgFH0y9mNbd98U8A319ufRmmcdf9U3A7VLvivu/SlwMv9XARfb7U7jeYbtMg/PLrxrqXzLkWdGG/FzfCZSZmL91G0Wq3CGRKBQDqf4ZRbnBqnxpwcIy8a0U9ldvenwYmXKL1ViWdHoU/Kc/d19bXd0S+5jUMd9O7+nVM3riG5ggNqUcLfGaIHZ8en/pN9dhb28Bl73C2ztbpIYkZdOS01MRP7oHNG15Wecw2Iq+kUV7zEqezLJCpfIPVqSVS8POrVfgNDtCdo
N7tYnE9eUbAstGdw